With the development of combination antiretroviral therapy(cART),human immunodeficiency virus(HIV)infection has transitioned from a generally fatal disease to a manageable chronic condition over the past two decades.[...With the development of combination antiretroviral therapy(cART),human immunodeficiency virus(HIV)infection has transitioned from a generally fatal disease to a manageable chronic condition over the past two decades.[1]cART provides rapid control of HIV and partial restoration of immune function,thus preventing various HIV-related complications.However,this does not mean that people living with HIV(PLWH)completely return healthy after receiving cART.展开更多
To the Editor:People living with the human immunodeficiency virus(PLWH)are more likely to develop cancers,have a more severe clinical course of cancers,and have a higher mortality than healthy population.Standard trea...To the Editor:People living with the human immunodeficiency virus(PLWH)are more likely to develop cancers,have a more severe clinical course of cancers,and have a higher mortality than healthy population.Standard treatments and immunotherapy like immunecheckpoint inhibitors(ICIs)used for cancer are being employed increasingly to treat non-acquired immune deficiency syndrome-defining cancers in PLWH because of an improvement in combined antiretroviral therapy(cART)efficacy and life expectancy.[1]Malignant tumor cells provoke suppression of immune checkpoints and promote immunosuppressive states,which favors evasion of the immune system and tumor growth.ICIs act by blocking inhibitory pathways through invigorating T cells and other innate cells and adaptive cells,thereby resulting in productive antitumor immune responses.展开更多
基金supported by the National Key R&D Program of China(No.2021YFC2301900-2021YFC2301901)
文摘With the development of combination antiretroviral therapy(cART),human immunodeficiency virus(HIV)infection has transitioned from a generally fatal disease to a manageable chronic condition over the past two decades.[1]cART provides rapid control of HIV and partial restoration of immune function,thus preventing various HIV-related complications.However,this does not mean that people living with HIV(PLWH)completely return healthy after receiving cART.
基金supported by grants from the National Key R&D Program of China(Nos.2022YFC2305202,2021YFC2301900-2021YFC2301901)
文摘To the Editor:People living with the human immunodeficiency virus(PLWH)are more likely to develop cancers,have a more severe clinical course of cancers,and have a higher mortality than healthy population.Standard treatments and immunotherapy like immunecheckpoint inhibitors(ICIs)used for cancer are being employed increasingly to treat non-acquired immune deficiency syndrome-defining cancers in PLWH because of an improvement in combined antiretroviral therapy(cART)efficacy and life expectancy.[1]Malignant tumor cells provoke suppression of immune checkpoints and promote immunosuppressive states,which favors evasion of the immune system and tumor growth.ICIs act by blocking inhibitory pathways through invigorating T cells and other innate cells and adaptive cells,thereby resulting in productive antitumor immune responses.
